| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -14,276 | -8,877 |
| Stock-based compensation expense | 614 | 559 |
| Paid-in-kind interest expense on promissory note | 100 | - |
| Depreciation and amortization | 867 | 483 |
| Fair value of common stock issued for services | - | 0 |
| Accounts receivable | 770 | 269 |
| Non-cash interest expense on promissory note | - | 100 |
| Operating lease liabilities, net | -74 | -67 |
| Prepaid expenses and other current assets | -228 | -98 |
| Deposits | -48 | -64 |
| Accounts payable | 948 | 608 |
| Accrued expenses | 315 | -127 |
| Other liabilities | 1,004 | 646 |
| Fair value of warrants issued for services | - | 0 |
| Contract liability | -455 | -508 |
| Net cash used in operating activities | -11,451 | -7,290 |
| Payment for acquisition, net of excess cash of 865 | 5,135 | 5,135 |
| Acquisitions of property and equipment | 810 | 893 |
| Net cash used in investing activities | -5,945 | -6,028 |
| Proceeds from issuance of debt | 9,225 | 9,642 |
| Proceeds from issuance of common stock | 2,775 | 347 |
| Proceeds from issuance of warrants | 1,699 | - |
| Proceeds from issuance of pre-funded warrants | 609 | - |
| Proceeds from exercise of warrants | 866 | 1,699 |
| Payments for issuance costs | 837 | 837 |
| Reduction of finance lease liability | 17 | - |
| Proceeds from issuance of pre-funded warrants | - | 609 |
| Reduction of debt liability | 97 | - |
| Net cash provided by financing activities | 14,223 | 11,460 |
| Net increase (decrease) in cash and cash equivalents | -3,173 | -1,858 |
| Cash and cash equivalents at beginning of period | 6,260 | - |
| Cash and cash equivalents at end of period | 3,087 | - |
Vivos Therapeutics, Inc. (VVOS)
Vivos Therapeutics, Inc. (VVOS)